Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD

被引:248
作者
Lewiecki, E. Michael [1 ]
Miller, Paul D.
McClung, Michael R.
Cohen, Stanley B.
Bolognese, Michael A.
Liu, Yu
Wang, Andrea
Siddhanti, Suresh
Fitzpatrick, Lorraine A.
机构
[1] New Mexico Clin Res & Osteoporosis Ctr, Albuquerque, NM USA
[2] Colorado Ctr Bone Res, Lakewood, CO USA
[3] Oregon Osteoporosis Ctr, Portland, OR USA
[4] Radiat Res, Dallas, TX USA
[5] Bethesda Hlth Res Ctr, Bethesda, MD USA
[6] Amgen Inc, Thousand Oaks, CA USA
关键词
denosumab; osteoporosis; BMD; bone turnover markers; RANKL;
D O I
10.1359/JBMR.070809
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Denosumab is a monoclonal antibody to RANKL. In this randomized, placebo-controlled study of 412 postmenopausal women with low BMD, subcutaneous denosumab given every 3 or 6 mo was well tolerated, increased BMD, and decreased bone resorption markers for up to 24 mo. Continued study of denosumab is warranted in the treatment of low BMD in postmenopausal women. Introduction: Denosumab is a fully human monoclonal antibody that inhibits RANKL, a key mediator of osteoclastogenesis and bone remodeling. This prespecified exploratory analysis evaluated the efficacy and safety of denosumab through 24 mo in the treatment of postmenopausal women with low BMD. Materials and Methods: Four hundred twelve postmenopausal women with lumbar spine BMD T-scores of -1.8 to -4.0 or femoral neck/total hip T-scores of -1.8 to -3.5 were randomly assigned to receive double-blind, subcutaneous injections of placebo; denosumab 6, 14, or 30 mg every 3 mo; denosumab 14, 60, 100, or 210 mg every 6 mo: or open-label oral alendronate 70 mg once weekly. Outcome measures included BMD at the lumbar spine, total hip, distal one-third radius, and total body; bone turnover markers; and safety. Results: Denosumab increased BMD at all measured skeletal sites and decreased concentrations of bone turnover markers compared with placebo at 24 mo. At the lumbar spine, BMD increases with denosumab ranged from 4.13% to 8.89%. BMD changes with denosumab 30 mg every 3 mo and >= 60 mg every 6 mo were similar to, or in some cases greater than, with alendronate. The incidence of adverse events was similar in the placebo, denosumab, and alendronate treatment groups. Exposure-adjusted adverse events over 2 yr of treatment were similar to those reported during the first year of treatment. Conclusions: In these postmenopausal women with low BMD, treatment with denosumab for 2 yr was associated with sustained increases in BMD and reductions in bone resorption markers compared with placebo.
引用
收藏
页码:1832 / 1841
页数:10
相关论文
共 26 条
[1]  
Atkinson J, 2005, J BONE MINER RES, V20, pS294
[2]   A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women [J].
Bekker, PJ ;
Holloway, DL ;
Rasmussen, AS ;
Murphy, R ;
Martin, SW ;
Leese, PT ;
Holmes, GB ;
Dunstan, CR ;
DePaoli, AM .
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (07) :1059-1066
[3]   A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer [J].
Body, JJ ;
Facon, T ;
Coleman, RE ;
Lipton, A ;
Geurs, F ;
Fan, M ;
Holloway, D ;
Peterson, MC ;
Bekker, P .
CLINICAL CANCER RESEARCH, 2006, 12 (04) :1221-1228
[4]   Osteoclast differentiation and activation [J].
Boyle, WJ ;
Simonet, WS ;
Lacey, DL .
NATURE, 2003, 423 (6937) :337-342
[5]   Kinetics of bone protection by recombinant osteoprotegerin therapy in lewis rats with adjuvant arthritis [J].
Campagnuolo, G ;
Bolon, B ;
Feige, U .
ARTHRITIS AND RHEUMATISM, 2002, 46 (07) :1926-1936
[6]   Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): A pharmacodynamic and pharmacokinetic analysis in rats [J].
Capparelli, C ;
Morony, S ;
Warmington, K ;
Adamu, S ;
Lacey, D ;
Dunstan, CR ;
Stouch, B ;
Martin, S ;
Kostenuik, PJ .
JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 (05) :852-858
[7]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[8]   Role of RANK ligand in mediating increased bone resorption in early postmenopausal women [J].
Eghbali-Fatourechi, G ;
Khosla, S ;
Sanyal, A ;
Boyle, WJ ;
Lacey, DL ;
Riggs, BL .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (08) :1221-1230
[9]   Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment [J].
Giuliani, N ;
Bataille, R ;
Mancini, C ;
Lazzaretti, M ;
Barillé, S .
BLOOD, 2001, 98 (13) :3527-3533
[10]   A SHARPER BONFERRONI PROCEDURE FOR MULTIPLE TESTS OF SIGNIFICANCE [J].
HOCHBERG, Y .
BIOMETRIKA, 1988, 75 (04) :800-802